SpectRx Expanding Clinical Study Of Continuous Glucose Monitoring System
This article was originally published in The Gray Sheet
Executive Summary
SpectRx says it is looking to enroll investigators for the next round of clinical studies of the company's evolving continuous glucose monitoring system prototypes.
You may also be interested in...
SpectRx/Welch Allyn Cervical Cancer Detection PMA Expected By 2002
Premarket approval application submission for a non-invasive cervical cancer detection system co-developed by SpectRx and Welch Allyn will occur in late 2001 or early 2002, SpectRx says.
SpectRx/Welch Allyn Cervical Cancer Detection PMA Expected By 2002
Premarket approval application submission for a non-invasive cervical cancer detection system co-developed by SpectRx and Welch Allyn will occur in late 2001 or early 2002, SpectRx says.
SpectRx/Abbott Labs
Sale of $2.8 mil. in SpectRx convertible redeemable preferred stock to Abbott is included in a joint pact to develop a continuous glucose monitor. An additional $2.5 mil. investment is anticipated Jan. 3. Expanding on an existing alliance between the firms, the revised agreement gives Abbott exclusive worldwide marketing rights to continuous monitoring as well as single-use monitoring applications of the SpectRx technology, which incorporates sensors worn on top of the skin to analyze glucose levels in interstitial fluid (1"The Gray Sheet" June 28, p. 19)